Expertise in
7
conditions

Dr. Lindsay Kilburn

Hematology | Oncology
Children's National Hospital
1400 Forest Glen Rd Ste 335, 
Silver Spring, MD 
Expertise in
7
conditions
Children's National Hospital
1400 Forest Glen Rd Ste 335, 
Silver Spring, MD 

Overview

Lindsay Kilburn is a Hematologist and an Oncologist practicing medicine in Silver Spring, Maryland.

Dr. Kilburn is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Diffuse Midline Glioma H3 K27M-Mutant, Brain Stem Cancer, Glioma, and Optic Glioma.

She is actively involved in clinical research, co-authoring 51 peer reviewed articles and participating in 17 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in TX

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

Children's National Hospital
1400 Forest Glen Rd Ste 335, Silver Spring, MD 20910

Additional Areas of Focus

Dr. Kilburn has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

PNOC021: A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients With Recurrent Low-Grade Gliomas and High Grade Gliomas
PNOC021: A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients With Recurrent Low-Grade Gliomas and High Grade Gliomas
Enrollment Status: Suspended
Publish Date: April 13, 2026
Intervention Type: Drug
Study Drugs: Everolimus, Trametinib
Study Phase: Phase 1
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 1
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2026
Intervention Type: Drug
Study Drug: Mirdametinib
Study Phase: Phase 2
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib
Study Phase: Phase 4
Phase 2 Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (AT/RT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed AT/RT
Phase 2 Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (AT/RT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed AT/RT
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Alisertib, Methotrexate, Cisplatin, Carboplatin, Cyclophosphamide, Etoposide, Topotecan, Vincristine
Study Phase: Phase 2
A Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas
A Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2026
Intervention Type: Drug
Study Drugs: BGB-290, Temozolomide
Study Phase: Phase 1
Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma
Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2026
Intervention Type: Biological
Study Drug: APX005M
Study Phase: Phase 1
A Phase I Study of Tovorafenib/DAY101 (Formerly TAK-580, MLN2480) for Children With Low-Grade Gliomas and Other RAS/RAF/MEK/ERK Pathway Activated Tumors
A Phase I Study of Tovorafenib/DAY101 (Formerly TAK-580, MLN2480) for Children With Low-Grade Gliomas and Other RAS/RAF/MEK/ERK Pathway Activated Tumors
Enrollment Status: Completed
Publish Date: February 19, 2026
Intervention Type: Drug
Study Drug: DAY101
Study Phase: Phase 1
PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
Enrollment Status: Completed
Publish Date: September 09, 2025
Intervention Type: Drug
Study Drug: Everolimus
Study Phase: Phase 2
Pediatric Neuro-Oncology Consortium (PNOC)-002: Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children and Young Adults With Recurrent/Refractory BRAFV600E- or BRAF Ins T Mutant Brain Tumors
Pediatric Neuro-Oncology Consortium (PNOC)-002: Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children and Young Adults With Recurrent/Refractory BRAFV600E- or BRAF Ins T Mutant Brain Tumors
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Drug
Study Drug: Vemurafenib
Study Phase: Early Phase 1
View 9 Less Clinical Trials

51 Total Publications

A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4.
A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4.
Journal: Neuro-oncology
Published: April 17, 2025
Similar Doctors
Expertise in
19
conditions
Dr. Sharon Savage
Hematology | Oncology
Expertise in
19
conditions
Dr. Sharon Savage
Hematology | Oncology

Office

9609 Medical Center Dr, 
Bethesda, MD 
 (1222.0 miles away)
240-276-7241
Languages Spoken:
English

Sharon Savage is a Hematologist and an Oncologist practicing medicine in Bethesda, Maryland. Dr. Savage is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Dyskeratosis Congenita, Aplastic Anemia, Aase Syndrome, Bone Marrow Transplant, and Hormone Replacement Therapy (HRT).

Expertise in
13
conditions
Dr. Blanche Alter
Hematology | Oncology
Expertise in
13
conditions
Dr. Blanche Alter
Hematology | Oncology

Office

9609 Medical Center Dr Rm 6E452, 
Rockville, MD 
 (1220.9 miles away)
240-276-7239
Languages Spoken:
English

Blanche Alter is a Hematologist and an Oncologist practicing medicine in Rockville, Maryland. Dr. Alter is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Aase Syndrome, Dyskeratosis Congenita, Aplastic Anemia, Bone Marrow Transplant, and Hormone Replacement Therapy (HRT).

Expertise in
18
conditions
Dr. Taofeek Owonikoko
Hematology | Oncology
Expertise in
18
conditions
Dr. Taofeek Owonikoko
Hematology | Oncology

Office

22 S Greene St # 9, 
Baltimore, MD 
 (1254.0 miles away)
410-328-6841
Languages Spoken:
English
See accepted insurances

Taofeek Owonikoko is a Hematologist and an Oncologist practicing medicine in Baltimore, Maryland. Dr. Owonikoko is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Tissue Biopsy.

Frequently Asked Questions about Dr. Lindsay Kilburn

How do I make an appointment with Dr. Lindsay Kilburn?

You can book an appointment with Dr. Lindsay Kilburn by calling their office at 202-476-5000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Lindsay Kilburn a top-rated expert for Diffuse Midline Glioma H3 K27M-Mutant?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lindsay Kilburn is classified as an Distinguished expert for Diffuse Midline Glioma H3 K27M-Mutant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Lindsay Kilburn specialize in?

While Dr. Lindsay Kilburn is a Hematology, they have specific expertise in Diffuse Midline Glioma H3 K27M-Mutant, Brain Stem Cancer, and Glioma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Lindsay Kilburn participate in research or clinical trials?

Yes. Dr. Lindsay Kilburn has published 51 articles and abstracts on conditions like Diffuse Midline Glioma H3 K27M-Mutant. You can view a list of Dr. Lindsay Kilburn's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Lindsay Kilburn accept my insurance?

Dr. Lindsay Kilburn accepts most major insurance plans, including Anthem BCBS and Highmark. We recommend calling the office directly at 202-476-5000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kilburn's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile